BET-IN-13

Modify Date: 2024-01-02 13:00:36

BET-IN-13 Structure
BET-IN-13 structure
Common Name BET-IN-13
CAS Number 2506823-08-9 Molecular Weight 497.56
Density N/A Boiling Point N/A
Molecular Formula C28H23N3O4S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of BET-IN-13


BET-IN-13 is a potent BET inhibitor with an IC50 value of 1.6 nM. BET-IN-13 reduces LPS-induced TNF-α, IL-1β, IL-6, and NOS2 mRNA expression levels. BET-IN-13 shows anti-inflammatory activity. BET-IN-13 has the potential for the research of acute liver injury[1].

 Names

Name BET-IN-13

 BET-IN-13 Biological Activity

Description BET-IN-13 is a potent BET inhibitor with an IC50 value of 1.6 nM. BET-IN-13 reduces LPS-induced TNF-α, IL-1β, IL-6, and NOS2 mRNA expression levels. BET-IN-13 shows anti-inflammatory activity. BET-IN-13 has the potential for the research of acute liver injury[1].
Related Catalog
Target

BRD4 BD1:57.4 nM (IC50)

BRD4 BD2:44.4 nM (IC50)

BRD2 BD1:79.3 nM (IC50)

BRD2 BD2:27.5 nM (IC50)

BRD3 BD1:45.6 nM (IC50)

BRD3 BD2:18.9 nM (IC50)

BRDT BD1:87.0 nM (IC50)

BRDT BD2:43.4 nM (IC50)

In Vitro BET-IN-13 (compound 28) (1.1, 3.3, 10 µM, 2+6 h) 降低 RAW264.7 细胞中 LPS (500 ng/ml) 诱导的 TNF-α、IL-1β、IL-6 和 NOS2 mRNA 的表达水平[1]。 RT-PCR[1] Cell Line: RAW264.7 cells Concentration: 1.1, 3.3, 10 µM Incubation Time: Pre-treated for 2 h before stimulating with LPS for 6 h Result: Significantly reduced LPS (500 ng/ml) induced TNF-α, IL-1β, IL-6 and NOS2 mRNA expression levels in a dose-dependent manner.
In Vivo BET-IN-13 (3 mg/kg;静脉注射;一次) 在小鼠中显示出良好的药代动力学 (PK) 特性,T1/2 为 0.69 h,AUCINF-obs 为 609 h*ng/mL 和 Vss 为 1717 mL/kg[1]。 BET-IN-13 (37.5、75 mg/kg;腹腔注射;一次) 降低 LPS/D-GalN(d-gaiactosamine)诱导的急性肝衰竭 (ALF) 小鼠的炎症和肝损伤而无明显毒性[1]。 Animal Model: 20-22g, Female C57BL/6J mice (LPS/D-GalN(d-gaiactosamine)-induced acute liver failure (ALF))[1] Dosage: 37.5, 75 mg/kg Administration: I.p.; once Result: Reduced inflammatory responses associated with LPS/GalN-induced acute liver failure with the survival rate increased significantly to 69.2% for37.5 mg/kg and to 84.6% for 75 mg/kg.
References

[1]. Chen C, et al. Cyclization strategy leads to highly potent Bromodomain and extra-terminal (BET) Bromodomain inhibitors for the treatment of acute liver injury. Eur J Med Chem. 2022 Dec 16;247:115023.  

 Chemical & Physical Properties

Molecular Formula C28H23N3O4S
Molecular Weight 497.56
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.